<DOC>
	<DOC>NCT00111540</DOC>
	<brief_summary>This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.</brief_summary>
	<brief_title>Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>The subject has an HbA1c value &lt;=11.0% The subject has a body mass index (BMI) of 25 kg/m^2 to 45 kg/m^2, inclusive Is currently treated with certain medications, including exogenous insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>exendin-4</keyword>
</DOC>